CY1117290T1 - Εμβολιο φυματιωσης και μεθοδος χρησης αυτου - Google Patents

Εμβολιο φυματιωσης και μεθοδος χρησης αυτου

Info

Publication number
CY1117290T1
CY1117290T1 CY20151100215T CY151100215T CY1117290T1 CY 1117290 T1 CY1117290 T1 CY 1117290T1 CY 20151100215 T CY20151100215 T CY 20151100215T CY 151100215 T CY151100215 T CY 151100215T CY 1117290 T1 CY1117290 T1 CY 1117290T1
Authority
CY
Cyprus
Prior art keywords
person
treatment vaccine
treatment
inactivated
mycobacterium
Prior art date
Application number
CY20151100215T
Other languages
Greek (el)
English (en)
Inventor
Jennifer Lighter
Jason Fisher
Original Assignee
Mico Bio, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mico Bio, Inc. filed Critical Mico Bio, Inc.
Publication of CY1117290T1 publication Critical patent/CY1117290T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20151100215T 2007-04-12 2015-03-02 Εμβολιο φυματιωσης και μεθοδος χρησης αυτου CY1117290T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92330107P 2007-04-12 2007-04-12
EP08745627.3A EP2144626B8 (en) 2007-04-12 2008-04-11 Tuberculosis vaccine and method of using same

Publications (1)

Publication Number Publication Date
CY1117290T1 true CY1117290T1 (el) 2017-04-26

Family

ID=39523390

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100215T CY1117290T1 (el) 2007-04-12 2015-03-02 Εμβολιο φυματιωσης και μεθοδος χρησης αυτου

Country Status (14)

Country Link
US (3) US8394389B2 (https=)
EP (1) EP2144626B8 (https=)
JP (2) JP5713672B2 (https=)
AU (1) AU2008240181B2 (https=)
CA (1) CA2682870C (https=)
CY (1) CY1117290T1 (https=)
DK (1) DK2144626T3 (https=)
ES (1) ES2531018T3 (https=)
HR (1) HRP20150177T1 (https=)
HU (1) HUE024427T2 (https=)
PL (1) PL2144626T3 (https=)
PT (1) PT2144626E (https=)
SI (1) SI2144626T1 (https=)
WO (1) WO2008128065A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150177T1 (hr) 2007-04-12 2015-04-10 Mico Bio, Inc. Cjepivo protiv tuberkuloze i postupak upotrebe tog cjepiva
WO2012137072A1 (en) 2011-04-06 2012-10-11 Biovaxim Limited Therapeutic vaccine compositions inducing tolerance to hiv for treating hiv infections in humans
AP2013007166A0 (en) 2011-04-06 2013-10-31 Univ Paris Descartes Inst De Rech Pour Le Dev Ird Pharmaceutical compositions for preventing and/or treating an HIV disease in humans
MX2013012165A (es) * 2011-04-20 2014-06-11 Mico Bio Inc Composicion y metodo para mejorar una respuesta inmune.
ES2438690B1 (es) * 2012-06-15 2015-01-16 Fundació Institut Per A La Investigació En Ciències De La Salut "Germans Trias I Pujol" (Igtp) Unitat De Tuberculosi Experimental Micobacterias inactivadas para su uso por vía oral en la prevención de la tuberculosis
EP2679232A1 (en) * 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria vaccination
EP2679677A1 (en) * 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria therapy
US9388400B2 (en) 2012-06-29 2016-07-12 Lysando Ag Composition for use in mycobacteria diagnosis
KR101615186B1 (ko) 2014-03-07 2016-04-25 연세대학교 산학협력단 결핵 백신의 면역효과 증강용 조성물 및 면역효과 증진 방법
KR101631054B1 (ko) * 2015-12-31 2016-06-16 중앙대학교 산학협력단 마이코박테리아 유래 CFP-10 또는 Ag85B에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편
US10279031B2 (en) * 2016-05-11 2019-05-07 Phibro Animal Health Corporation Composition comprising antigens and a mucosal adjuvant and a method for using
WO2018006939A1 (en) 2016-07-05 2018-01-11 Universidad De Zaragoza Inactivated tuberculosis vaccine
CN108743931B (zh) * 2018-05-02 2022-08-16 成都威斯克生物医药有限公司 抗结核病疫苗及其制备方法和用途
ES2962407T3 (es) 2018-12-04 2024-03-18 Sabiotec Spin Off S L Inmunoestimulante para su uso contra patógenos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
US4724114A (en) 1984-04-23 1988-02-09 Kimberly-Clark Corporation Selective layering of superabsorbents in meltblown substrates
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
DE60226175T2 (de) 2001-11-14 2009-07-09 Novavax, Inc. Mycobakterieller impfstoff
BR0303367A (pt) * 2002-03-08 2004-07-20 Bakulesh Mafatlal Khamar Células de mycobacterium w, veìculo farmaceuticamente aceitável, preservativo, ruptura de mycobacterium w, extração de solvente, enzimas usadas para a extração enzimática de células de mycobacterium w, adjuvante, composição farmacêutica, tensoativo, e, concentração de tensoativo do processo de fabricar uma composição farmacêutica para a administração de tuberculose
CA2612900C (en) * 2005-06-23 2016-08-09 Claus Aagaard Improved tuberculosis vaccines
HRP20150177T1 (hr) 2007-04-12 2015-04-10 Mico Bio, Inc. Cjepivo protiv tuberkuloze i postupak upotrebe tog cjepiva

Also Published As

Publication number Publication date
US8932608B2 (en) 2015-01-13
EP2144626B8 (en) 2015-02-18
EP2144626A2 (en) 2010-01-20
CA2682870A1 (en) 2008-10-23
AU2008240181B2 (en) 2014-01-09
PT2144626E (pt) 2015-03-03
AU2008240181A1 (en) 2008-10-23
SI2144626T1 (sl) 2015-04-30
US20130273110A1 (en) 2013-10-17
WO2008128065A2 (en) 2008-10-23
US9636391B2 (en) 2017-05-02
DK2144626T3 (en) 2015-02-09
JP2015038130A (ja) 2015-02-26
US8394389B2 (en) 2013-03-12
WO2008128065A3 (en) 2008-12-18
JP2010523711A (ja) 2010-07-15
US20100112007A1 (en) 2010-05-06
CA2682870C (en) 2016-08-09
EP2144626B1 (en) 2014-12-03
JP5713672B2 (ja) 2015-05-07
HRP20150177T1 (hr) 2015-04-10
ES2531018T3 (es) 2015-03-09
US20150258187A1 (en) 2015-09-17
PL2144626T3 (pl) 2015-09-30
HUE024427T2 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
CY1117290T1 (el) Εμβολιο φυματιωσης και μεθοδος χρησης αυτου
CY1122187T1 (el) Αντιγονικη συνθεση μυκοβακτηριου
CY1119753T1 (el) Λυσινικη αλφα αζτρεοναμη
CY1108875T1 (el) Βλεννοπροσφυτικα σκευασματα που περιεχουν ξυλογλυκανη και ειναι χρησιμα σε ιατρικες συσκευες και σε φαρμακευτικα σκευασματα
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
CY1109119T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
CL2023000087A1 (es) Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral
BRPI0408236A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um composto, e, métodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito de tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
GB0201508D0 (en) Organic compounds
CY1106476T1 (el) Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
CY1115082T1 (el) Υποκατεστημενα παραγωγα 1,3-διφαινυλπροπανιου, παρασκευες και χρησεις αυτων
CY1105080T1 (el) Ενωσεις θειενοπυρρολυλιου και φουρανοπυρρολυλιου και η χρηση τους ως συνδετες η4 υποδοχεα ισταμινης
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
EP1545599A4 (en) IMMUNOGENIC COMPOSITIONS AND ITS DIAGNOSTIC AND THERAPEUTIC USES
DE60330708D1 (de) Impfstoff gegen das west-nile-virus
CY1122892T1 (el) Παραγωγα 3-(καρβοξυμεθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
CY1117504T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, και cx3cr1
CY1125704T1 (el) Ενωσεις c-μαννοσιδιου χρησιμες για τη θεραπεια μολυνσεων ουροποιητικης οδου
CY1107480T1 (el) Χρηση aivlosin για την θepαπευτικη αγωγη και προληψη λοιμωξεων lawsonia σε χοιρους
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
BR112018012009A2 (pt) terapia neoadjuvante para câncer de bexiga
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer